WallStSmart

InMode Ltd (INMD)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 9477% more annual revenue ($35.48B vs $370.50M). INMD leads profitability with a 25.3% profit margin vs 13.0%. MDT appears more attractively valued with a PEG of 1.50. INMD earns a higher WallStSmart Score of 58/100 (C).

INMD

Buy

58

out of 100

Grade: C

Growth: 3.3Profit: 8.0Value: 4.7Quality: 8.5
Piotroski: 2/9Altman Z: 8.64

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INMDSignificantly Overvalued (-46.5%)

Margin of Safety

-46.5%

Fair Value

$9.72

Current Price

$13.75

$4.03 premium

UndervaluedFair: $9.72Overvalued
MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$86.58

$62.24 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INMD6 strengths · Avg: 9.5/10
P/E RatioValuation
9.5x10/10

Attractively priced relative to earnings

Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
8.6410/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
25.3%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability
25.0%8/10

Strong operational efficiency at 25.0%

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

INMD4 concerns · Avg: 2.5/10
Market CapQuality
$857.24M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
2.902/10

Expensive relative to growth rate

EPS GrowthGrowth
-63.5%2/10

Earnings declined 63.5%

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : INMD

The strongest argument for INMD centers on P/E Ratio, Price/Book, Debt/Equity. Profitability is solid with margins at 25.3% and operating margin at 25.0%.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : INMD

The primary concerns for INMD are Market Cap, Piotroski F-Score, PEG Ratio.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

INMD profiles as a mature stock while MDT is a value play — different risk/reward profiles.

INMD carries more volatility with a beta of 2.19 — expect wider price swings.

MDT is growing revenue faster at 8.7% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

INMD scores higher overall (58/100 vs 56/100), backed by strong 25.3% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

InMode Ltd

HEALTHCARE · MEDICAL DEVICES · USA

InMode Ltd. designs, develops, manufactures and markets minimally invasive aesthetic medical products based on its proprietary RF-assisted lipolysis and deep subdermal fractional RF technologies. The company is headquartered in Yokneam, Israel.

Visit Website →

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?